CytoTools Appoints Dr. Rüdiger Weseloh Of Merck Serono To Its Advisory Board

• Resignation of advisory board member Dr. Johannes Holzmeister necessitates a successor

• As his successor, Dr. Rüdiger Weseloh takes up his mandate as planned

Darmstadt, 26th May 2015 – Dr. Rüdiger Weseloh, currently Senior Director at Merck Serono in Darmstadt, will become a new member of the advisory board of CytoTools AG. The change became necessary after CytoTools advisory board member Dr. Johannes Holzmeister took on the position of CEO of the Swiss biotech company Cardiorentis. This work will involve long periods of time abroad in the USA. Therefore, he can no longer fulfil his duties on the advisory board of CytoTools to the necessary extent, but he will remain available to the company as an expert consultant. However, the CytoTools AG had already presented Dr. Rüdiger Weseloh to its shareholders as a replacement board member at the last annual general meeting in July 2014. As foreseen at his election, he will now succeed as planned in case of a resignation, thus ensuring a smooth transition.

Dr. Rüdiger Weseloh has been a Senior Director at Merck Serono since 2010, and there he heads the department for strategic transactions and leads the negotiations for the acquisition of licences for new active substance candidates. Previously, Dr. Weseloh, who studied biochemistry and obtained a doctorate as a neuroscientist, had worked as an equity analyst for two private banks in Frankfurt and Cologne.

Dr. Mark-Andre Freyberg, CEO of CytoTools AG, commented; "I would like to thank Dr. Holzmeister for his work on the advisory board at CytoTools, and of course I understand that he must concentrate his energies on his newly assigned tasks. We were though suitably foresighted and have been able to acquire a further excellent advisory board member in Dr. Weseloh. He has a great deal of experience in sales and licensing. This knowledge will be of high value for CytoTools in the coming months. I therefore am very pleased to welcome him to the advisory board of CytoTools AG."

This press release contains specific future-oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future- oriented statements made. CytoTools is not obligated to update these future-oriented statements.

About CytoTools:

CytoTools AG is a German biotechnology company focused on translating fundamental biology research on the mechanisms of cell growth and programmed cell death into unique therapies that are designed to treat the cause of the disease rather than the symptoms. The Company has developed a robust and diverse pipeline of disease modifying therapies that comprise proprietary small molecules and biologics. These have the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (57%) and CytoPharma GmbH (42%).

Contact:
CytoTools AG
Dr. Mark Andre Freyberg
Klappacher Str. 126
D-64285 Darmstadt
Tel.: +49-6151-95158-12
Fax: +49-6151-95158-13
E-mail: [email protected]

Press and Investor Relations:
Instinctif Partners
Dr. Robert Mayer/Ursula Querette
Rindermarkt 5
D-80331 Munich
Tel.: +49-89-3090 5189-13
E-mail: [email protected]

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.